Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2022 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and...
March 29, 2022 07:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

-- Achieved $11.2 Million in Net Revenue in 2021 ---- Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives ---- KPI-012 Phase 1b Clinical Data Accepted for...
March 23, 2022 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and...
March 08, 2022 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare

-- Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives -- ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a...
February 18, 2022 16:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ARLINGTON, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement...
December 17, 2021 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
November 18, 2021 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
November 15, 2021 08:47 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

-- Achieved $3.1 Million in Net Revenue in 3Q 2021 ---- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021-- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio ---- Conference...
November 15, 2021 08:45 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated...
November 15, 2021 07:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call

WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...